Today, Alloplex Biotherapeutics Inc. announced the appointment of Dr. Andre Goy, MD, to its Scientific Advisory Board.

Dr. Goy is Physician in Chief of Hackensack Meridian Health Oncology Care Transformation Service; Chairman & Chief Physician Officer of John Theurer Cancer Center (JTCC) at Hackensack University Medical Center; Lydia Pfund Chair for Lymphoma; Academic Chairman Oncology at Hackensack Meridian School of Medicine at Seton Hall University and Professor of Medicine at Georgetown University.

Since 2011, Dr. Goy also initiated CAR T-cell therapy at John Theurer Cancer Center, in collaboration with the team of Steve Rosenberg at the National Cancer Institute. He was also instrumental in developing JTCC’s Tissue Bank which has now grown to become one of the largest bone marrow transplant programs in the Tri-State area engaged in innovative studies.

Commenting on the appointment, Dr. Frank Borriello, Scientific Founder & CEO of Alloplex Biotherapeutics, said “It is both an honor and a pleasure to welcome Dr. Andre Goy to the Alloplex Scientific Advisory Board. Dr. Goy brings not only a wealth of experience and knowledge to Alloplex but a forward looking and enthusiastic embrace of advanced cellular therapies that will be invaluable to us as we initiate our clinical development program.”

“I am delighted to accept Frank Borriello’s invitation to join Alloplex Biotherapeutics’ Scientific Advisory Board, said Dr. Goy. “I believe we are at an inflection point in medicine as illustrated by the acceleration in the pace of innovation that will truly reshape cancer care. In particular, the future will be, in large part, cell-based therapies. The approach offered by SUPLEXA therapeutic cells is very appealing for multiple reasons: from an easier manufacturing process, favourable toxicity profile, likely enhanced durability of the cells and efficacy as suggested by preclinical data showing pan cancer sensitivity,” he said.

---

About Dr. André Goy

Dr Goy is the Physician in Chief for Oncology for Hackensack Meridian Health (HMH) network and also Chair of John Theurer Cancer Center the leading and premier Cancer Program in NJ.

 As Chief of the Division of Lymphoma at JTCC, Dr. Goy leads New Jersey’s largest program for lymphoma treatment and research. He has trained and/or worked at some of the world’s leading medical institutions, including Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, University Hospitals Group of Paris, and The Pasteur Institute in Paris.

Dr. Goy received his degree in Medicine from University Joseph Fourier. He holds two Masters of Science Degrees: one in the field of Tumour Immunology from Institute Pasteur and University Pierre & Marie Curie, Paris VI; the other in the field of Experimental Oncology from University Le Kremlin-Bicetre, Paris.

---

About Alloplex Biotherapeutics, Inc.

Alloplex Biotherapeutics is a clinic-ready company focused on developing SUPLEXA; a potential first-in-class autologous, pan-cancer therapy for the treatment of cancer patients. The privately-held company was established in 2016 by Scientific Founder and CEO, Dr. Frank Borriello, MD, PhD.

About SUPLEXA Therapeutic Cells

SUPLEXA Therapeutic Cells are an autologous cellular therapy intended to treat cancer. They are manufactured from peripheral white blood cells (PBMC). Following a short ex vivo activation procedure, the PBMC are differentiated into a mixed population of cells comprised of NK, NK-T and T cells. SUPLEXA therapeutic cells are capable of recognizing and lysing a broad range of tumor cells without harming normal cells. SUPLEXA is cultured ex-vivo and administered by IV.